Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Meta-analysis to evaluate the role of interferon in follicular lymphoma.

Rohatiner AZ, Gregory WM, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A, Fisher RI, Unterhalt M, Arranz R, Chisesi T, Aviles A, Lister TA.

J Clin Oncol. 2005 Apr 1;23(10):2215-23. Epub 2005 Jan 31.

PMID:
15684317
2.

A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma.

Rohatiner A, Radford J, Deakin D, Earl H, Love SB, Price O, Wilson A, Lister TA.

Br J Cancer. 2001 Jul 6;85(1):29-35.

3.

Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691.

Smith SM, Johnson J, Cheson BD, Canellos G, Petroni G, Oken M, Duggan D, Hurd D, Gockerman JP, Parker B, Prchal J, Peterson BA; Cancer and Leukemia Group B.; Eastern Cooperative Oncology Group..

Leuk Lymphoma. 2009 Oct;50(10):1606-17. doi: 10.1080/10428190903093807.

PMID:
19626540
4.

Cost-Effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma.

Wirt DP, Giles FJ, Oken MM, Solal-Celigny P, Beck JR.

Leuk Lymphoma. 2001 Feb;40(5-6):565-79.

PMID:
11426529
5.

Chemotherapy plus interferon-alpha2b versus chemotherapy in the treatment of follicular lymphoma.

Neri N, Avilés A, Cleto S, Díaz N, Talavera A, García EL, Díaz-Maqueo JC.

J Hematother Stem Cell Res. 2001 Oct;10(5):669-74.

PMID:
11672513
6.

Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making.

Cole BF, Solal-Céligny P, Gelber RD, Lepage E, Gisselbrecht C, Reyes F, Sebban C, Sugano D, Tendler C, Goldhirsch A.

J Clin Oncol. 1998 Jul;16(7):2339-44.

PMID:
9667248
7.

Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a.

Davis TA, Maloney DG, Grillo-López AJ, White CA, Williams ME, Weiner GJ, Dowden S, Levy R.

Clin Cancer Res. 2000 Jul;6(7):2644-52.

8.

Interferon alfa for the treatment of follicular lymphomas.

Hiddemann W, Griesinger F, Unterhalt M.

Cancer J Sci Am. 1998 Jul;4 Suppl 2:S13-8. Review.

PMID:
9672770
9.

[IFN-alpha consolidation after intensive chemotherapy does not bring any survival advantage in low-grade non-Hodgkin lymphoma].

Klee M, Illiger HJ.

Strahlenther Onkol. 2001 Sep;177(9):494-5. German. No abstract available.

PMID:
11591024
10.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
11.

Recombinant interferon-alpha therapy in patients with follicular lymphoma.

Ozer H, Wiernik PH, Giles F, Tendler C.

Cancer. 1998 May 15;82(10):1821-30. Review. Erratum in: Cancer 1998 Aug 1;83(3):593.

PMID:
9587113
12.

Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.

Papaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H, Stevens J.

Health Technol Assess. 2012;16(37):1-253, iii-iv. Review.

13.

Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.

Vidal L, Gafter-Gvili A, Leibovici L, Dreyling M, Ghielmini M, Hsu Schmitz SF, Cohen A, Shpilberg O.

J Natl Cancer Inst. 2009 Feb 18;101(4):248-55. doi: 10.1093/jnci/djn478. Epub 2009 Feb 10. Review.

PMID:
19211444
14.

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.

Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M, Hess G, Truemper L, Diehl V, Kropff M, Kneba M, Schmitz N, Metzner B, Pfirrmann M, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group..

Blood. 2004 Nov 1;104(9):2667-74. Epub 2004 Jul 6.

15.

Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.

Morris GJ, Millenson MM, Padavic-Shaller K, Wang H, Rogatko A, Clyde J, Boyd RL, Yeslow G, Halbherr T, Schilder RJ, Smith MR.

Haematologica. 2004 Dec;89(12):1484-91.

16.

Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin's lymphoma.

Allen IE, Ross SD, Borden SP, Monroe MW, Kupelnick B, Connelly JE, Ozer H.

J Immunother. 2001 Jan-Feb;24(1):58-65.

PMID:
11211149
17.
18.

Interferon alpha 2b as maintenance therapy improves outcome in follicular lymphoma.

Avilés A, Neri N, Huerta-Guzmán J, Pérez F, Sotelo L.

Leuk Lymphoma. 2004 Nov;45(11):2247-51.

PMID:
15512813
19.

Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.

Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, Dölken G, Naumann R, Knauf W, Freund M, Rohrberg R, Höffken K, Franke A, Ittel T, Kettner E, Haak U, Mey U, Klinkenstein C, Assmann M, von Grünhagen U; East German Study Group Hematology and Oncology Study..

J Clin Oncol. 2007 May 20;25(15):1986-92. Epub 2007 Apr 9.

PMID:
17420513
20.

Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.

Solal-Celigny P, Lepage E, Brousse N, Reyes F, Haioun C, Leporrier M, Peuchmaur M, Bosly A, Parlier Y, Brice P, et al.

N Engl J Med. 1993 Nov 25;329(22):1608-14.

Supplemental Content

Support Center